Irina P. Nikishina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Irina P. Nikishina has a total of 536 co-authors. Here are the top co-authors by number of shared publications:
- Mariya I. Kaleda
V.A. Nasonova Research Institute of Rheumatology
30 shared publications - Svetlana Olegovna Salugina
V.A. Nasonova Research Institute of Rheumatology
11 shared publications Alberto Martini
Clinic of Paediatrics and Rheumatology, IRCCS Istituto Giannina Gaslini, University of Genoa, Genoa, Italy; Scientific Directory, IRCCS Istituto Giannina Gaslini, University of Genoa, Genoa, Italy; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Sciences, University of Genoa, Genoa, Italy
8 shared publications- Ekaterina I. Alekseeva
Department of Pediatric Rheumatology, National Medical Research Center of Children’s Health, Moscow 119991, Russia
8 shared publications - Svetlana V. Arsenyeva
V.A. Nasonova Research Institute of Rheumatology
8 shared publications - Valeriya G. Matkava
V.A. Nasonova Research Institute of Rheumatology
8 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 132-135
Resolution of the Expert Council “Reproductive health of patients with rheumatic diseases during targeted therapy: from preconception preparation to postpartum follow-up”
On June 19, 2026, a meeting of the Expert Council was held to discuss reproductive health issues in patients with immune-mediated inflammatory rheumatic diseases and the safety of antirheumatic therapy. Rheumatologists, obstetrician-gynecologists, reproductive medicine specialists, and other experts participated in the discussion.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 132-135
Open AccessResolution of the Expert Council “Reproductive health of patients with rheumatic diseases during targeted therapy: from preconception preparation to postpartum follow-up”
On June 19, 2026, a meeting of the Expert Council was held to discuss reproductive health issues in patients with immune-mediated inflammatory rheumatic diseases and the safety of antirheumatic therapy. Rheumatologists, obstetrician-gynecologists, reproductive medicine specialists, and other experts participated in the discussion.
- Open Access
- 19 March 2026
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 106 (6) , 235-242
A Unique Clinical Case of Heterotopic Ossification Volume Reduction in a Child with Fibrodysplasia Ossificans Progressiva Based on Whole-Body Multislice Computed Tomography
Fibrodysplasia ossificans progressiva (FOP) is an extremely rare genetic disorder inherited in an autosomal dominant manner. The FOP development is caused by a mutation in the ACVR1 gene, which encodes a receptor for bone morphogenetic protein, leading to uncontrolled formation of heterotopic ossifications (HO) and causing complete immobility of the patient. Low-dose multislice computed tomography (LDCT) is considered a “gold standard” for assessing the localization and extent of HO lesions. In addition to its high spatial resolution, LDCT combined with specialized software enables quantitative volumetric measurement of HO areas, which can be extremely valuable for monitoring disease progression. We present a clinical case of FOP in a 2-year-old child, for whom whole-body LDCT was performed for the first time in the Russian Federation, followed by calculation of the total HO volume visualized during examination using integrated software tools.
- 19 March 2026
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 106 (6) , 235-242
Open AccessA Unique Clinical Case of Heterotopic Ossification Volume Reduction in a Child with Fibrodysplasia Ossificans Progressiva Based on Whole-Body Multislice Computed Tomography
Fibrodysplasia ossificans progressiva (FOP) is an extremely rare genetic disorder inherited in an autosomal dominant manner. The FOP development is caused by a mutation in the ACVR1 gene, which encodes a receptor for bone morphogenetic protein, leading to uncontrolled formation of heterotopic ossifications (HO) and causing complete immobility of the patient. Low-dose multislice computed tomography (LDCT) is considered a “gold standard” for assessing the localization and extent of HO lesions. In addition to its high spatial resolution, LDCT combined with specialized software enables quantitative volumetric measurement of HO areas, which can be extremely valuable for monitoring disease progression. We present a clinical case of FOP in a 2-year-old child, for whom whole-body LDCT was performed for the first time in the Russian Federation, followed by calculation of the total HO volume visualized during examination using integrated software tools.
- Open Access
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 71-79
Use of palovarotene in pathogenetic therapy of fibrodysplasia ossificans progressiva: real-world clinical practice experience
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare monogenic disease manifested by an uncontrolled process of generalized heterotopic ossification. The first and only drug that has demonstrated in clinical trials the ability to slow the growth of new ossifications is palovarotene (PVT), a selective agonist of the gamma subtype of the retinoic acid receptor (RARã), which has been approved for the treatment of FOP in certain age groups in several countries. Published real-world data on its use are limited. Objective: to analyze the experience of using PVT in FOP in real-world Russian clinical practice, with an emphasis on detailed patients’ characteristics description and assessment of treatment efficacy and safety. Material and methods. Nineteen patients with severe FOP (mean age 12.4 years; 14 patients younger than 14 years) who met the selection criteria were chosen for PVT therapy. Progression of the total volume of heterotopic ossifications (HO) was assessed using low-dose whole-body computed tomography (LDCT). The number of flare-ups before and during therapy was analyzed. Functional status was assessed using the CAJIS and CHAQ scales. Adverse events (AEs) occurring during treatment were recorded. Results and discussion. All 19 patients with FOP had the classic disease phenotype with a pathogenic variant of the ACVR1 gene. Of these, 15 are currently receiving PVT in the ongoing regimen in combination with the Janus kinase inhibitor tofacitinib (TOFA); in 8 of these patients, treatment duration exceeds 1 year (median 18 months). Another 4 patients are awaiting access to the drug. According to serial LDCT examinations with a 12-month interval, no substantial increase in the total HO volume was detected. No deterioration in functional status was observed during therapy. No serious AEs were recorded. In 14 of 15 patients, mucocutaneous AEs (dryness, pruritus, retinoid dermatitis) of varying severity were observed. Conclusion. Preliminary analysis of PVT use in patients with FOP showed no significant progression of HO and, at the same time, a favorable safety profile. Complementarity of the pathogenetic effects of PVT and TOFA may become a new therapeutic strategy for FOP.
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 71-79
Open AccessUse of palovarotene in pathogenetic therapy of fibrodysplasia ossificans progressiva: real-world clinical practice experience
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare monogenic disease manifested by an uncontrolled process of generalized heterotopic ossification. The first and only drug that has demonstrated in clinical trials the ability to slow the growth of new ossifications is palovarotene (PVT), a selective agonist of the gamma subtype of the retinoic acid receptor (RARã), which has been approved for the treatment of FOP in certain age groups in several countries. Published real-world data on its use are limited. Objective: to analyze the experience of using PVT in FOP in real-world Russian clinical practice, with an emphasis on detailed patients’ characteristics description and assessment of treatment efficacy and safety. Material and methods. Nineteen patients with severe FOP (mean age 12.4 years; 14 patients younger than 14 years) who met the selection criteria were chosen for PVT therapy. Progression of the total volume of heterotopic ossifications (HO) was assessed using low-dose whole-body computed tomography (LDCT). The number of flare-ups before and during therapy was analyzed. Functional status was assessed using the CAJIS and CHAQ scales. Adverse events (AEs) occurring during treatment were recorded. Results and discussion. All 19 patients with FOP had the classic disease phenotype with a pathogenic variant of the ACVR1 gene. Of these, 15 are currently receiving PVT in the ongoing regimen in combination with the Janus kinase inhibitor tofacitinib (TOFA); in 8 of these patients, treatment duration exceeds 1 year (median 18 months). Another 4 patients are awaiting access to the drug. According to serial LDCT examinations with a 12-month interval, no substantial increase in the total HO volume was detected. No deterioration in functional status was observed during therapy. No serious AEs were recorded. In 14 of 15 patients, mucocutaneous AEs (dryness, pruritus, retinoid dermatitis) of varying severity were observed. Conclusion. Preliminary analysis of PVT use in patients with FOP showed no significant progression of HO and, at the same time, a favorable safety profile. Complementarity of the pathogenetic effects of PVT and TOFA may become a new therapeutic strategy for FOP.
- Open Access
- 30 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 79
Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period
Background/Objectives: This study aimed to evaluate the pharmacokinetics (PK), effectiveness, and safety of the direct interleukin-6 (IL-6) inhibitor olokizumab (OKZ) in adolescent patients with active polyarticular juvenile idiopathic arthritis (pJIA) who had an inadequate response or intolerance to methotrexate (MTX). Methods: We analyzed results from an open-label, single-arm trial of OKZ therapy at a dose of 64 mg every 4 weeks for 24 weeks. We evaluated pharmacokinetic (PK) parameters, clinical effectiveness, serum C-reactive protein (CRP) dynamics, and adverse events (AEs). Results: Sixteen patients were included in the study, of whom 13 (81.2%) received OKZ through Week 24. The PK profile was consistent with observations in adults with rheumatoid arthritis (RA). By Week 16, 12 (80%) patients achieved an ACRpedi30 response, 11 (73.3%) achieved an ACRpedi50 response, and 2 (13.3%) reached inactive disease status. This response was sustained through Week 24, and no disease flares were observed. A trend toward a better response was noted among patients with baseline CRP > 10 mg/L, higher baseline IL-6, and those naïve to biologic DMARDs. Twelve patients (75.0%) experienced twenty-three mild or moderate AEs. Infections were the most frequent AEs (in 6 patients, 37.5%). No serious AEs or deaths occurred. Conclusions: OKZ treatment reduced pJIA disease activity and was well tolerated. The safety profile was consistent with that of other IL-6 inhibitors, and the PK profile matched that seen in adult RA patients.
- 30 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 79
Open AccessOpen-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period
Background/Objectives: This study aimed to evaluate the pharmacokinetics (PK), effectiveness, and safety of the direct interleukin-6 (IL-6) inhibitor olokizumab (OKZ) in adolescent patients with active polyarticular juvenile idiopathic arthritis (pJIA) who had an inadequate response or intolerance to methotrexate (MTX). Methods: We analyzed results from an open-label, single-arm trial of OKZ therapy at a dose of 64 mg every 4 weeks for 24 weeks. We evaluated pharmacokinetic (PK) parameters, clinical effectiveness, serum C-reactive protein (CRP) dynamics, and adverse events (AEs). Results: Sixteen patients were included in the study, of whom 13 (81.2%) received OKZ through Week 24. The PK profile was consistent with observations in adults with rheumatoid arthritis (RA). By Week 16, 12 (80%) patients achieved an ACRpedi30 response, 11 (73.3%) achieved an ACRpedi50 response, and 2 (13.3%) reached inactive disease status. This response was sustained through Week 24, and no disease flares were observed. A trend toward a better response was noted among patients with baseline CRP > 10 mg/L, higher baseline IL-6, and those naïve to biologic DMARDs. Twelve patients (75.0%) experienced twenty-three mild or moderate AEs. Infections were the most frequent AEs (in 6 patients, 37.5%). No serious AEs or deaths occurred. Conclusions: OKZ treatment reduced pJIA disease activity and was well tolerated. The safety profile was consistent with that of other IL-6 inhibitors, and the PK profile matched that seen in adult RA patients.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 109-114
Autoimmune manifestations in primary immunodeficiencies
According to current understanding of the mechanisms underlying primary immunodeficiencies (PIDs) and their clinical course, there is a clear and clinically significant association between this group of disorders and autoimmune manifestations (AIMs).This article presents up-to-date information on AIMs in patients with PIDs, with a focus on the most common conditions and key clinical features that warrant consideration of PIDs in the differential diagnosis of patients with rheumatic diseases.
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 109-114
Open AccessAutoimmune manifestations in primary immunodeficiencies
According to current understanding of the mechanisms underlying primary immunodeficiencies (PIDs) and their clinical course, there is a clear and clinically significant association between this group of disorders and autoimmune manifestations (AIMs).This article presents up-to-date information on AIMs in patients with PIDs, with a focus on the most common conditions and key clinical features that warrant consideration of PIDs in the differential diagnosis of patients with rheumatic diseases.
- Open Access
- 16 May 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (4) , 4371
Achievements in Russian Pediatric Rheumatology: Meeting of the Internal Medicine Sciences’ Council of the Department of Medical Sciences of the Russian Academy of Sciences
25.11.2024 состоялось очередное заседание Совета по терапевтическим наукам Секции клинической медицины РАН, которое было посвящено достижениям детской ревматологии в России. Целью данного Заседания стало обсуждение актуальных вопросов педиатрической ревматологической практики.
- 16 May 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (4) , 4371
Open AccessAchievements in Russian Pediatric Rheumatology: Meeting of the Internal Medicine Sciences’ Council of the Department of Medical Sciences of the Russian Academy of Sciences
25.11.2024 состоялось очередное заседание Совета по терапевтическим наукам Секции клинической медицины РАН, которое было посвящено достижениям детской ревматологии в России. Целью данного Заседания стало обсуждение актуальных вопросов педиатрической ревматологической практики.
- Open Access
- 19 February 2025
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 22 (1) , 19-30
The First Russian Experience of Using Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva: Two Case Reports
Background. Fibrodysplasia ossificans progressiva (FOP) — is an extremely rare genetic disorder with an autosomal dominant type of inheritance. FOP is associated with a genetically determined disorder caused by the presence of a specific mutation in the ACVR1/ALK2 gene encoding the bone morphogenetic protein receptor. FOP is clinically manifested by the unrestrained formation of heterotopic ossifications, leading to a gradual progression of disability up to complete immobility of the patient. At an early age, the disease can be recognized by the presence of characteristic phenotypic stigmas, mainly the characteristic malformation of the thumbs, confirming the diagnosis by molecular genetic analysis. Early diagnosis of FOP avoids unnecessary iatrogenic manipulations and slows down the progression of the disease. Up until recently, there was no therapy that had a pathogenetic effect, preventing the development of ossifications. The first and only drug that has proven its effectiveness as a result of clinical trials and is registered for use in patients with FOP in a number of countries is palovarotene.Case reports: The publication presents the first Russian experience of using palovarotene with a description of two clinical observations of patients with a genetically confirmed diagnosis of FOP. The clinical picture, the difficult path to diagnosis, and the encouraging experience of treating patients, including anti-inflammatory therapy using Janus kinase inhibitors (tofacitinib) and pathogenetic therapy with palovarotene, are described.Conclusion. The aggressive nature of the course of FOP, which inevitably leads to severe disability of patients, necessitates the widespread attention of practitioners to the early diagnosis of FOP, an in-depth study of the factors determining progression, and new opportunities for pathogenetic therapy allow us to count on improving the prognosis of this extremely serious disease.
- 19 February 2025
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 22 (1) , 19-30
Open AccessThe First Russian Experience of Using Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva: Two Case Reports
Background. Fibrodysplasia ossificans progressiva (FOP) — is an extremely rare genetic disorder with an autosomal dominant type of inheritance. FOP is associated with a genetically determined disorder caused by the presence of a specific mutation in the ACVR1/ALK2 gene encoding the bone morphogenetic protein receptor. FOP is clinically manifested by the unrestrained formation of heterotopic ossifications, leading to a gradual progression of disability up to complete immobility of the patient. At an early age, the disease can be recognized by the presence of characteristic phenotypic stigmas, mainly the characteristic malformation of the thumbs, confirming the diagnosis by molecular genetic analysis. Early diagnosis of FOP avoids unnecessary iatrogenic manipulations and slows down the progression of the disease. Up until recently, there was no therapy that had a pathogenetic effect, preventing the development of ossifications. The first and only drug that has proven its effectiveness as a result of clinical trials and is registered for use in patients with FOP in a number of countries is palovarotene.Case reports: The publication presents the first Russian experience of using palovarotene with a description of two clinical observations of patients with a genetically confirmed diagnosis of FOP. The clinical picture, the difficult path to diagnosis, and the encouraging experience of treating patients, including anti-inflammatory therapy using Janus kinase inhibitors (tofacitinib) and pathogenetic therapy with palovarotene, are described.Conclusion. The aggressive nature of the course of FOP, which inevitably leads to severe disability of patients, necessitates the widespread attention of practitioners to the early diagnosis of FOP, an in-depth study of the factors determining progression, and new opportunities for pathogenetic therapy allow us to count on improving the prognosis of this extremely serious disease.
- Open Access
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 369-376
Current concept of osteoporosis diagnosis and treatment in children
Osteoporosis (OP) is a disease characterized by a decrease in bone strength, leading to an increased risk of fractures. Bone fragility in children may be due to genetic disorders, chronic underlying conditions or taking medications that negatively affect bone metabolism. The article considers the modern classification of OP in children, approaches to its diagnosis, the role of dual-energy X-ray absorptiometry for diagnosis.The main goal of OP prevention and treatment is to achieve a higher peak of bone mass, improve bone microarchitectonics, and, as in adults, reduce the risk of fractures, prevent skeletal deformities, improve mobility, independence and quality of life. Recommendations for lifestyle changes are presented, including adequate calcium intake and vitamin D, taking antiresorptive drugs, as well as prospective management of children with OP.
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 369-376
Open AccessCurrent concept of osteoporosis diagnosis and treatment in children
Osteoporosis (OP) is a disease characterized by a decrease in bone strength, leading to an increased risk of fractures. Bone fragility in children may be due to genetic disorders, chronic underlying conditions or taking medications that negatively affect bone metabolism. The article considers the modern classification of OP in children, approaches to its diagnosis, the role of dual-energy X-ray absorptiometry for diagnosis.The main goal of OP prevention and treatment is to achieve a higher peak of bone mass, improve bone microarchitectonics, and, as in adults, reduce the risk of fractures, prevent skeletal deformities, improve mobility, independence and quality of life. Recommendations for lifestyle changes are presented, including adequate calcium intake and vitamin D, taking antiresorptive drugs, as well as prospective management of children with OP.
- Open Access
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 385–393
Belimumab in the treatment of systemic lupus erythematosus with juvenile onset: Results of a single-center retrospective study
The treatment of systemic lupus erythematosus with juvenile onset (jSLE) remains a difficult task, taking into account the more aggressive course of the disease, requiring the appointment of various therapy regimens, including mainly a combination of high doses of glucocorticoids (GC) with immunosuppressive drugs, which on the one hand improves control by the course of the disease, but on the other hand leads to an increase in serious adverse effects from therapy. Modern therapy capabilities have improved significantly with the advent of the belimumab – first and alone registered biologics for children with SLE.The aim of the study – based on an open single-center retrospective study, to analyze the efficacy and safety of belimumab in children with SLE.Material and methods. The study included all patients with jSLE who were observed in the pediatric department of V.A. Na sonova Research Institute of Rheumatology and received at least 1 infusion of belimumab. Diagnosis of SLE based on 2012 SLICC (Systemic Lupus Erythematosus International Collaborating Clinics) criteria. The efficacy of therapy was evaluated among patients who received belimumab for 6 months or more, and safety in all who received at least 1 infusion.Results. The study included 31 patients, 24 girls/7 boys. The median (Me) age at onset of the disease was 12.6 [10.18; 13.5] years, the Me duration of the disease at the time of initiation of belimumab therapy was 2.15 [0.9; 4.4] years. The Me activity on the SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) at the time of diagnosis verification was 12 [9; 17.5], at the time of start of belimumab – 8 [6; 12], 35.5% patients had severe activity, 51.6% – moderate, 12.9% – mild activity. The dose of GC per os at start of belimumab was 15 [10; 21.25] mg/day, 32.26% of patients received a high dose of GC, 54.84% – moderate dose, 12.9% – low dose. 9 patients had SDI (Systemic Lupus International Collaborating Clinics Damage Index) ≥1, Me – 1 [1; 2]. After 6 months of therapy, the Me of disease activity according to SLEDAI was 4 [2; 6], the dose of GC per os was reduced to 10 [8.25; 17.5] mg/day. In 15 patients, a decrease in antiDNA was recorded (57.7% of those who initially had elevated values of antiDNA), in 9 the level of complement was normalized (50% of those who initially had hypocomplementemia). After 12 months of therapy, the Me of SLEDAI was 4 [2; 4] (p=0.034), the dose of GC per os was 5 [5; 8.125] mg/day (p=0.012). 5 patients completed therapy within 12 months or more: 1 patient – remission, 4 patients – secondary inefficiency. Belimumab treatment was well tolerated, with the exception of three cases of serious adverse reactions (9.7%): prolonged diarrheal syndrome (after the 1st infusion), Lyell’s syndrome (after the 2nd infusion), infusion reaction (during the 2nd infusion). During the therapy of belimumab, no new damage were recorded; in 2 patients there was a decrease in the SDI.Conclusion. Belimumab therapy in patients with jSLE demonstrated high efficacy with a decrease in the activity of the disease according to SLEDAI, normalization of antiDNA and complement, the possibility of a significant reduction the dose of GC, the absence of progression of the SDI with a good safety profile in the vast majority of patients.
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 385–393
Open AccessBelimumab in the treatment of systemic lupus erythematosus with juvenile onset: Results of a single-center retrospective study
The treatment of systemic lupus erythematosus with juvenile onset (jSLE) remains a difficult task, taking into account the more aggressive course of the disease, requiring the appointment of various therapy regimens, including mainly a combination of high doses of glucocorticoids (GC) with immunosuppressive drugs, which on the one hand improves control by the course of the disease, but on the other hand leads to an increase in serious adverse effects from therapy. Modern therapy capabilities have improved significantly with the advent of the belimumab – first and alone registered biologics for children with SLE.The aim of the study – based on an open single-center retrospective study, to analyze the efficacy and safety of belimumab in children with SLE.Material and methods. The study included all patients with jSLE who were observed in the pediatric department of V.A. Na sonova Research Institute of Rheumatology and received at least 1 infusion of belimumab. Diagnosis of SLE based on 2012 SLICC (Systemic Lupus Erythematosus International Collaborating Clinics) criteria. The efficacy of therapy was evaluated among patients who received belimumab for 6 months or more, and safety in all who received at least 1 infusion.Results. The study included 31 patients, 24 girls/7 boys. The median (Me) age at onset of the disease was 12.6 [10.18; 13.5] years, the Me duration of the disease at the time of initiation of belimumab therapy was 2.15 [0.9; 4.4] years. The Me activity on the SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) at the time of diagnosis verification was 12 [9; 17.5], at the time of start of belimumab – 8 [6; 12], 35.5% patients had severe activity, 51.6% – moderate, 12.9% – mild activity. The dose of GC per os at start of belimumab was 15 [10; 21.25] mg/day, 32.26% of patients received a high dose of GC, 54.84% – moderate dose, 12.9% – low dose. 9 patients had SDI (Systemic Lupus International Collaborating Clinics Damage Index) ≥1, Me – 1 [1; 2]. After 6 months of therapy, the Me of disease activity according to SLEDAI was 4 [2; 6], the dose of GC per os was reduced to 10 [8.25; 17.5] mg/day. In 15 patients, a decrease in antiDNA was recorded (57.7% of those who initially had elevated values of antiDNA), in 9 the level of complement was normalized (50% of those who initially had hypocomplementemia). After 12 months of therapy, the Me of SLEDAI was 4 [2; 4] (p=0.034), the dose of GC per os was 5 [5; 8.125] mg/day (p=0.012). 5 patients completed therapy within 12 months or more: 1 patient – remission, 4 patients – secondary inefficiency. Belimumab treatment was well tolerated, with the exception of three cases of serious adverse reactions (9.7%): prolonged diarrheal syndrome (after the 1st infusion), Lyell’s syndrome (after the 2nd infusion), infusion reaction (during the 2nd infusion). During the therapy of belimumab, no new damage were recorded; in 2 patients there was a decrease in the SDI.Conclusion. Belimumab therapy in patients with jSLE demonstrated high efficacy with a decrease in the activity of the disease according to SLEDAI, normalization of antiDNA and complement, the possibility of a significant reduction the dose of GC, the absence of progression of the SDI with a good safety profile in the vast majority of patients.
- Open Access
- 21 August 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (4) , 99-105
Modern treatment options for systemic lupus erythematosus in children (literature review)
The treatment of juvenile-onset systemic lupus erythematosus (jSLE) is a complex task in view of the diversity of clinical manifestations and the course of the disease as well as the high risk of organ damage. The need to create separate therapeutic principles for jSLE is justified by the greater intensification of therapy due to both the doses used and the combination of a larger number of different drugs in a patient. However, the basis for the treatment of jSLE today is mainly the extrapolation of data obtained in studies with adult patients. The review reflects modern ideas about the spectrum of drugs used in jSLE, with particular emphasis on efficacy, safety and timing of therapy as well as possible optimization options.
- 21 August 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (4) , 99-105
Open AccessModern treatment options for systemic lupus erythematosus in children (literature review)
The treatment of juvenile-onset systemic lupus erythematosus (jSLE) is a complex task in view of the diversity of clinical manifestations and the course of the disease as well as the high risk of organ damage. The need to create separate therapeutic principles for jSLE is justified by the greater intensification of therapy due to both the doses used and the combination of a larger number of different drugs in a patient. However, the basis for the treatment of jSLE today is mainly the extrapolation of data obtained in studies with adult patients. The review reflects modern ideas about the spectrum of drugs used in jSLE, with particular emphasis on efficacy, safety and timing of therapy as well as possible optimization options.